STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study
Stat News • 2/23/2026
Summary
Novo's next-generation obesity drug has encountered difficulties in a comparison study with a product from Lilly. This information is part of a broader update on biotech news provided by The Readout.
Advertisement
Lindy Score Breakdown (V4.2)
55d
Age
1
Sources
from cluster
1334
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1334/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1334/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 55 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about Lilly weight loss pill trial results, slashed U.K. clinical trial times, and more
Stat News • 2 days ago
STAT+: Cell therapy primed liver transplant patients to avoid organ rejection, small study shows
Stat News • 2 days ago
STAT+: The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades
Stat News • Today
STAT+: A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment
Stat News • 2 days ago
STAT+: Up and down the ladder: The latest comings and goings
Stat News • 2 days ago
STAT+: FDA eyes expanding testosterone therapy for libido
Stat News • 2 days ago
The deadly consequences of ICE detention
Stat News • 2 days ago
Opinion: Don’t believe headlines saying that vaccine skepticism is widespread
Stat News • 2 days ago
How Trump is pushing psychedelics reform through the health agencies
Stat News • 1 day ago
Opinion: The podcast bringing together MAHA and public health for hard conversations
Stat News • 1 day ago